PAHC
Phibro Animal Health Corp
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2014-04-11
$37.65
-1.09 (-2.81%)
last quote
Want the full multi-source brief on PAHC?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$37.65
High
$39.53
Low
$37.36
Previous close
$38.74
Fundamentals
Market cap
$1.57B
P/E (TTM)
15.77x
P/S (TTM)
1.04x
P/B
3.30x
Gross margin
33.33%
Operating margin
12.81%
Net margin
6.57%
Rev growth (YoY)
17.12%
EPS growth (YoY)
105.25%
ROE
28.67%
52W high
$60.08
52W low
$28.25
Beta
0.41x
Industry peers
by market cap
Upcoming earnings
next 60 days
2027-02-02in 89 days
Q2 2027EPS est $0.96
2026-11-04todayafter market
Q1 2027EPS est $0.81
Recent SEC filings
CIK 1069899filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 19h
BDX Gears Up to Report Q4 Results: How to Play the Stock?
BD heads into Q4 earnings with expectations of higher profits despite lower revenues, backed by strength in Interventional, Medical Essentials and Biologics.
Yahoo · 23h
Can Pharmacy Growth Offset Evernorth's Profit Decline in Cigna's Q3?
CI's Q3 revenues are poised to rise on pharmacy and premium growth, but declining Evernorth profits and higher medical costs could weigh on earnings.
Yahoo · 1d
Mettler-Toledo's Q3 Earnings on Deck: What's in Store for the Stock?
MTD's Q3'26 results are expected to benefit from improving markets, automation demand, acquisitions and growth across key regions.
Yahoo · 1d
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
Yahoo · 4d
Cencora Gears Up to Report Q4 Results: How to Play the Stock?
COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.
Yahoo · 4d
Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?
RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
Yahoo · 4d
STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?
STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.
Yahoo · 5d
ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock Falls
Align Technology's Q3 earnings and revenues beat estimates on higher aligner shipments, but a lowered 2026 sales outlook weighs on shares.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial